Summary:
- Pittsburgh-based biotech company Plexision received a $365K investment from the Richard King Mellon Foundation.
- The funds will be used to enhance the company’s blood tests through AI and ML capabilities for improved transplant outcome predictions.
- Plexision’s tests focus on personalized management of transplant rejection, infections in immunocompromised patients, and immune therapy in oncology.
Article:
Plexision Secures Investment to Enhance Blood Tests for Transplant Outcomes
Plexision, a biotechnology company based in Pittsburgh, recently announced a significant investment of $365K from the Richard King Mellon Foundation. The exact amount of the deal was not disclosed, but the funds will play a crucial role in advancing the company’s suite of cell-based blood tests.
The primary focus of this investment is to accelerate the integration of artificial intelligence (AI) and machine learning (ML) capabilities into Plexision’s tests. By leveraging these technologies, the company aims to enhance the predictive accuracy of complex transplant outcomes, ultimately improving patient care and treatment strategies.
Plexision’s range of tests caters to various aspects of personalized medicine, including transplant rejection, infections in immunocompromised patients, and immune therapy in oncology. The company’s reference laboratory offers FDA-approved tests like Pleximmune for predicting transplant rejection in pediatric patients with liver or intestine transplants, as well as other specialized tests for kidney transplant rejection and antibody-mediated rejection.
In addition to transplant-related tests, Plexision also provides diagnostic tools for measuring cell-mediated immunity to viruses like cytomegalovirus and Epstein-Barr virus. These tests are vital for managing infections in vulnerable patient populations and guiding treatment decisions effectively.
Moreover, Plexision actively engages in custom research and development projects that involve cellular biomarkers for drug development, vaccine research, and gene therapy products. By offering tailored solutions across various phases of product development, the company contributes to the advancement of personalized medicine and precision healthcare.
In conclusion, Plexision’s commitment to leveraging cutting-edge technologies and innovative approaches in blood testing underscores its dedication to improving patient outcomes and revolutionizing personalized medicine. With the support of the Richard King Mellon Foundation, the company is well-positioned to make significant strides in the field of biotechnology and healthcare.
